References
- Stone JH, McDowell PJ, Jayne DRW, et al. The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time. Semin Arthritis Rheum. 2022;55:152010.
- Fanouriakis A, Kostopoulou M, Alunno A, et al. Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
- Chung SA, Langford CA, Maz M, et al. American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021;73(8):1088–1105.
- Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3–18.
- Imaizumi C, Ogura T, Inoue Y, et al. Reduced rate of disease flares in Japanese patients with systemic lupus erythematosus: an altered balance between the use of glucocorticoids and immunosuppressants in recent decades. Intern Med. 2022;61:3189–3196.
- Kameda H, Suzuki M, Takeuchi T. Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases. Drug Target Insight. 2007;2:239–247.
- Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018;27:1984–2009.
- Morinobu A. JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med. 2020;43:148–155.
- Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86(5):1603–1607.
- Wilks, AF. The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol. 2008;19:319–328.
- Wilks AF, Harpur AG, Kurban RR, et al. Two novel protein-tyrosine kinases, each with a second phsphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol. 1991;11(4):2057–2065.
- Cance WG, Craven RJ, Weiner TM, et al. Novel protein kinases expressed in human breast cancer. Int J Cancer. 1993;54(4):571–577.
- Takahashi T, Shirasawa T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett. 1994;342(2):124–128.
- Kawamura M, McVicar DW, Johnston JA, et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A. 1994;91(14):6374–6378.
- Krolewski JJ, Lee R, Eddy R, et al. Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene. 1990;5:277–282.
- Firmbach-Kraft I, Byers M, Shows T, et al. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene. 1990;5:1329–1336.
- Schindler CW. JAK-STAT signaling in human disease. J Clin Invest. 2002;109:1133–1137.
- Tanaka Y, Luo Y, O’Shea JJ, et al. Janus kinase-targeting therapies in rheumatology: a mechanism-based approach. Nat Rev Rheumatol. 2022;18:133–145.
- Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93:373–383.
- Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385–395.
- Neubauer H, Cumano A, Müller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93(3):397–409.
- Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377(6544):65–68.
- Park SY, Saijo K, Takahashi T, et al. Development defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity. 1995;3:771–782.
- Karaghiosoff M, Neubauer H, Lassnig C, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity. 2000;13:549–560.
- Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity. 2000;13:561–571.
- Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of argan allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875–878.
- Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62:8973–8995.
- Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80:71–81.
- Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signaling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865–875.
- Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316–326.
- U.S. Food & Drug Administration. Drug Safety Communication. Tofacitinib, baribitinib, and upadacitinib. 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death.
- European Medicines Agency. Issued on 11 November 2022 (EMA/860610/2022). 2022. https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-referral-ema-confirms-measures-minimise-risk-serious-side_en-0.pdf.